Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury

Russell, Clark D; Millar, Jonathan; Baillie, J Kenneth

doi:10.1016/s0140-6736(20)30317-2

Cited by 1,812 publications

(1,814 citation statements)

References 19 publications

Supporting

Mentioning

1,704

Contrasting

Unclassified

Order By: Relevance

“…A variety of other agents, including antiviral peptides and corticosteroids have been shown to be effective in vitro and/or in animal models [40,41]. However, clinical evidence does not support the use of corticosteroid treatment for SARS-CoV-2 lung injury [42]. Vaccines that have been developed are either not effective, or in some cases have been reported to be involved in the selection of novel pathogenic CoVs via recombination of circulating strains [12,22,40].…”

Section: Lack Of Effective Treatmentmentioning

confidence: 99%

The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China

Yang

Peng

Wang

et al. 2020

Journal of Autoimmunity

865

828

View full text Add to dashboard Cite

COVID-19 pandemic, an unprecedented devastation, humanity needs an urgent cure to save the mankind from this deadly disease. Over six million people have been infected worldwide, with 6.3% reported deaths till date. SARS-CoV-2 virus, responsible for Novel Coronavirus (COVID-19) disease has been isolated recently and the vaccine's development is at nascent stage. At present, there are a few anecdotal evidences that anti-viral/anti-in ammatory/anti-malarial drugs can mitigate the disease. In the present study, we envision the potency of traditional Indian medicinal compounds that can be used as an effective drug. The viral SARS Coronavirus E protein plays a key role in virus life cycle and can be a potential drug target for the development of anti-SARS-CoV-2 drugs. Using the crystal structure of the CoVE protein, we performed virtual PyRX screening of Indian medicinal compounds which are reported to have e cacy in the treatment of some viral infections. Molecular docking studies were evaluated based on scores analysed by CavityPlus. The herbal compounds used were found to be more e cient in inhibiting the virus as compared to commercially available drugs. The results showed that β-boswellic acid and Glycyrrhizic acid possessed the best binding as a ligand with target molecule having binding a nity of-9.1 kcal/mol amongst eleven compounds screened. The study demonstrated that these are found to be strong SARS-CoV-2E protein inhibitors as they revealed compatible, near perfect dock in the overlapping region of functional viral protein pockets. These potential hit compounds can pave a way for designing of anti-viral therapeutics.

show abstract

Section: Lack Of Effective Treatmentmentioning

confidence: 99%

The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China

Yang

Peng

Wang

et al. 2020

Journal of Autoimmunity

865

828

View full text Add to dashboard Cite

show abstract

“…The difference in the use of glucocorticoid may be explained by the condition of patients with AKI that was more severe , thus physicians tended to use glucocorticoid in the most critically ill patients, even if there is a controversy on the use of glucocorticoid in COVID-19 patients. 22,23 However, the oral antiviral drugs, including arbidol (umifenovir), oseltamivir, lopinavir and ritonavir, were preferred in moderate patients on admission. Given that ACE2 is a functional receptor for SARS-CoV-2, the safety and potential effects of RAAS inhibitors in patients with COVID-19 should be carefully considered.…”

Section: Discussionmentioning

confidence: 99%

“…eGFR was calculated with Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. 22 The date of disease onset was defined as the day when the first symptom was noticed. Data are presented as number/total (percentage) or mean ± SD; COVID-2019, coronavirus disease 2019; eGFR, estimated glomerular filtration.…”

Section: Data Sourcesmentioning

confidence: 99%

Kidney disease is associated with in-hospital death of patients with COVID-19

Cheng

Luo

Wang

et al. 2020

Kidney International

2,327

178

2,580

View full text Add to dashboard Cite

“…In a metanalaysis of corticosteroid use in SARS patients, 4 studies provided conclusive evidence of harm (psychosis, diabetes, avascular necrosis and delayed viral clearance) 27 . Therefore, the use of steroids is controversial and not recommended by WHO due to potential inhibition of viral clearance and prolongation of the duration of viremia 28 .…”

Section: Glucocorticoidsmentioning

confidence: 99%